| Literature DB >> 24410911 |
Su Hee Jang1, Dong Il Kim, Min-Sun Choi.
Abstract
BACKGROUND: During their reproductive years about 10% of women experience some kind of symptoms before menstruation (PMS) in a degree that affects their quality of life (QOL). Acupuncture and herbal medicine has been a recent favorable therapeutic approach. Thus we aimed to review the effects of acupuncture and herbal medicine in the past decade as a preceding research in order to further investigate the most effective Korean Medicine treatment for PMS/PMDD.Entities:
Mesh:
Year: 2014 PMID: 24410911 PMCID: PMC3898234 DOI: 10.1186/1472-6882-14-11
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Figure 1Flow chart. Search and selection criteria conducted in accordance with PRISMA statement criteria. (Preferred Reporting Items for Systematic Reviews and Meta-Analyses).
Risk of bias of included RCTs*
| Chou (2008) [ | L | U | U | U | L | L |
| Kim (2005) [ | U | U | U | U | H | H |
| Habek (2002) [ | U | U | U | U | U | U |
| Shin (2009) [ | U | U | H | H | U | U |
| Xu (2006) [ | U | U | U | U | U | U |
| Xu (2006) [ | U | U | U | U | U | U |
| Guo (2004) [ | U | U | U | U | U | U |
| Hong (2002) [ | U | U | U | U | U | U |
| Yu (2006) [ | L | L | U | U | U | U |
| Ma (2010) [ | L | L | U | U | U | U |
| He (2009) [ | U | U | U | U | U | U |
| Atmaca (2003) [ | U | U | L | L | U | L |
| Zamani (2012) [ | U | L | L | L | L | L |
| Canning (2010) [ | U | L | L | L | U | L |
| Hicks (2004) [ | U | L | L | L | U | L |
| Masumeh (2010) [ | U | U | U | U | U | U |
| Agha-Hosseini (2008) [ | L | L | L | L | L | L |
*Domains of quality assessment based on the Cochrane tools for assessing risk of bias.
Abbreviations; Llow risk of bias, H high risk of bias, U unclear (uncertain risk of bias).
Therapeutic effect of acupuncture on premenstrual syndrome
| 1 | SP6 CV6 + LR3, LR2, SP10, LI4 or + ST368 | 13 @ L/FP | 10 | Not reported | MSSL | 7.56 ± 2.36 | SI 5 | None reported | P < 0.05 |
| 2/wk, 8 wks (2 cycles) | 16.78 ± 4.30 | ST 40 | |||||||
| (10) | |||||||||
| 2 | DU20 LI4 H3 REN3,4,6 PE6 GB34 UB23, Auriculoacu-point Shenmen9 | 2 ~ 4 @ LP | 18 | Not reported | Diagnosed as PMS | 77.8% reduction | Sham acupuncture | One subcutaneous abdominal hematoma | p < 0.008 |
| (1 cycle) | (17) | ||||||||
| 3 | Hand acupuncture therapy10 | 10 @ L/FP | 7 | Not reported | MSSL | 3.94 ± 1.66 | No treatment received | No serious AE observed | p < 0.001 |
| A5,A6,A8,A12,A16,A18,N18,F6 | 3/wk, 4 wks | 20.63 ± 10.32 | (10) | ||||||
| (1 cycle) | |||||||||
| 4 | Hand moxibustion therapy10 | 10 @ L/FP | 8 | Not reported | MSSL | 3.40 ± 1.78 | No treatment received | None reported | p < 0.001 |
| A5,A6,A8,A12,A16,A18,N18,F6 | 3/wk, 4 wks | 20.65 ± 6.12 | (10) | ||||||
| (1 cycle) | |||||||||
| 5 | Back-Shu points11 | 30 @ LP | 20 | Not reported | Met Chinese standards for diagnosis for PMS | Better than CG | Standard acupuncture | None reported | p < 0.05 |
| BL15,17,18,20,21,23 | 7/wk | score n/a | (20) | ||||||
| (3 cycles) | |||||||||
| 6 | Point-through-point12 | 30 @ LP | 30 | Not reported | Diagnosed for PMS by OB/GYN textbook | Better than CG | Medication - progestin (medroxyprogesterone, 6 mg daily) (30) | None reported | p < 0.05 |
| GV3 ~ 8 BL18 ~ 23 BL47 ~ 52 | 7/wk | score n/a | |||||||
| (3 cycles) | |||||||||
| 7 | BL17,18,20,23 GV20 CV4,17 SP6 PC6 LR313 | 30 @ LP | 31 | Not reported | Diagnosed as DSM-IV-TR | Better than CG | Medication - medroxy-progesterone 4 mg, diazepam 2.5 mg twice daily (31) | None reported | p < 0.05 |
| 7/wk | score n/a | ||||||||
| (3 cycles) | |||||||||
| 8 | Electroacupuncture on scalp14 | 30 @ L/FP | 35 | Not reported | Diagnosed as PMS by OB/GYN textbook | Better than CG | Medication - medroxy-progesterone 4 mg, diazepam 2.5 mg twice daily (35) | None reported | p < 0.05 |
| MS1,5 + MS2,3,4 | 3/wk | score n/a | |||||||
| (3 cycles) | |||||||||
| 9 | GV20 Ex-HN3,5 SP6,10 + LR3 CV17 LR14 Ex-CA1 CV4 SP9 ST36 CV6 PC6 HT7 BL23 GV4 KI315 | 21 @ LP | 30 | Not reported | Met ICD-10 criteria | Better than CG | Sham acupuncture | Two hypo menorrhea during 2nd cycle | p < 0.05 |
| 3 ~ 4/wk | score n/a | Selection of points N/A | |||||||
| (3 cycles) | (33) |
Literatures yield 9 studies as interventions. It comprises of acupuncture points and technique, treatment sessions marking the period of the session (either at luteal phase (LP) or at both LP and follicular phase as L/FP, Duration of the session as in weeks and by menstrual cycles, Baseline score and the outcome score, the control type, and p-value.
*n/a, not available; NS, not significantly different between groups; CG, control group.
The effect of herbal medicine for premenstrual syndrome
| 10 | Vitex Agnus castus17** (VAC, BNO 1095) 40 mg -Tablet | 1/day | 33 | Confirmed | PMSD sum score 29.38 ± 7.63 (p = 0.752) | PMSD sum score 14.66 ± 0.52 | Placebo | No notable AE observed | =0.0001 |
| (3 cycles) | (34) | ||||||||
| 11 | Vitex Agnus castus18 (VAC, BNO 1095, 4.0 mg of dried ethanolic (70%)) 40 mg -Tablet | 2/day | 101 | Confirmed | PMSD 29.13 ± 7.88 (p = 0.4017) | PMSD 6.41 ± 7.94 | Placebo | No serious AE observed | <0.05 |
| (3 cycles) | PMTS 26.17 ± 4.79 (p = 0.1649) | PMTS 9.92 ± 9.01 | (101) | ||||||
| 12 | Vitex Agnus castus extract19** (AC extract) | 1/day | 19 | Confirmed | DSR 171.758.1 (p > 0.05) HAM-D 15.24.7 (p > 0.05) CGI-SI 4.11.4 (p > 0.05) | DSR 82.849.5 | Fluoxetine | No serious AE observed from TG | >0.1 |
| HAM-D 7.64.3 | (19) | ||||||||
| 20-40 mg –Tablet | (2 cycles) | CGI-I 1.20.7 five symptoms diminished 50% or more | 2CG: Sexual dysfunction | ||||||
| 13 | Vitex Agnus castus20 (Vitex agnus extract) | 1/day | 62 | Confirmed | DSR 30% higher score @ LP | Better than CG | Placebo | No serious AE observed | <0.0001 |
| @ LP | (66) | ||||||||
| 40 drops (4.5 mg) -Liquid | (6 cycles) | ||||||||
| 14 | Hypericum Perforatum21 | 2/day | 17 | Confirmed | DSR score in LP 12.6 | DSR score 5.80 (F [1,30] = 4.82; p = 0.04; partial Z2 = 0.14) | Placebo | No serious AE observed | >0.05 |
| (Li 160 (80% methanolic dry extract, 0.18% hypericin, 3.38% hyperforin) 900 mg -Tablet | (2 cycles) | (15) | |||||||
| 15 | Hypericum Perforatum22 (St. John’s wart extract, 300 mg of extract, 900 ug of hypericin) 1800ug hypericin (600 mg) -Tablet | 2/day | 64 | Confirmed | MD score 326.33§ | MD score 230.28 (p ≤ 0.007) | Placebo | No serious AE observed | <0.007 |
| (61) | |||||||||
| (2 cycles) | |||||||||
| 16 | Hypericum Perforatum23 | 2/day | 85 | Confirmed | DSR 149.07 | DSR 86.13 | 2 Cellulose | No serious AE observed | <0.05 |
| (extract N/A) two 1340 ug hypericin -Tablet | (2 cycles) | Anxiety 41.15 ± 9.74 Crying 20.52 ± 11.73 Depression 29.26 ± 7.49 Craving 22.01 ± 11.03 Hydration 36.13 ± 8.50 | Anxiety 23.08 ± 14.78 (p = 0.223) Crying 5.87 ± 10.23 (p = 0.001, 71% reduction) Depression 13.82 ± 6.48 (p < 0.001, 52% reduction) Craving 17.26 ± 7.41 (p < 0.001) Hydration 26.10 ± 10.18 (p < 0.090) | Tablets | |||||
| (85) | |||||||||
| 17 | Xiao Yao San or Dan Zhi Xiao Yao San8 -Powder form | 3/day | 31 | Confirmed | Diagnosed as PMS | Physical MDQ 68.9% reduction | Placebo | No AE | <0.001 |
| @ LP | Physical MDQ psychological MDQ BDI ANX ANG PSS diagnosed as PMS (p < 0.005) | Psychological MDQ 74.8% reduction | (30) | ||||||
| (3 cycles) | |||||||||
| BDI 43.1% reduction ANX 23.8% reduction ANG 39.3% reduction PSS 16.4% reduction (p < 0.001) | |||||||||
| 18 | Crocus sativus (saffron) 24 30 mg -Tablet | 2/day | 24 | Confirmed | DSR < 50 PMS diagnosed by HDRS | 50% reduction in severity of symptoms by DSR and HDRS (P < 0.001) | Placebo | No severe AE reported | <0.001 |
| (2 cycles) | (23) | ||||||||
| 19 | Elsholtzia splendens 25 120 mg -Tablet | 1/day | 10 | Not recorded | BDI 33.50 ± 5.82 | BDI 23.60 ± 4.79 (p < 0.01) STAI 48.10 ± 5.20 (p < 0.05) STAI 52.00 ± 6.18 | Placebo | None reported | <0.01 |
| | (3 cycles) | STAI 58.40 ± 7.30 | (10) | ||||||
| PAF 270.20 ± 82.61 | |||||||||
| PAF 176.7 ± 61.33 (p = 0.530) | |||||||||
| 20 | Cirsium japonicum25 120 mg -Tablet | 1/day | 10 | Not recorded | BDI 33.60 ± 8.8 | BDI 30.40 ± 5.40 | Placebo | None reported | <0.01 |
| (3 cycles) | STAI 50.90 ± 9.50 | STAI 52.00 ± 6.18 | (10) | ||||||
| PAF 257.30 ± 74.81 | PAF 185.6 ± 53.65 | ||||||||
| 21 | Ginkgo biloba L.26 40 mg -Tablet | 3/day | 45 | Confirmed | Overall score 34.80 (p = 0.930) Severity of psychological symptoms 38.41 (p = 0.899) | Overall score 11.11 (p < 0.001) Severity of psychological symptoms 10.89 (p < 0.001) | Placebo | No severe AE reported | <0.001 |
| @ LP | (45) | ||||||||
| (2 cycles) |
Literatures yield 11 studies and 7 different herbs. It includes total dosage per day, number of times the herbs were taken per day dither at all phases or only during luteal phase (@ LP), the duration of the studies by menstrual cycles, sample size (Treatment Group: TG), two menstrual cycles of prospective ratings, baseline score using assessment tools used at each studies, the outcome measures and results, control types with number of analyzed: CG), and p-value.
*M, Measurement; PMSD, Premenstrual Syndrome Diary (four-point rating scale); PMTS, The Premenstrual Tension Syndrome Self-Rating Scale; DSR, Daily Symptom Report; PAF, Premenstrual Assessment Form;HDRS, Hamilton Depression Rating Scale (17-item); MD, Menstrual Diary(made up of 25 symptoms); MDQ, menstrual distress questionnaire); BDI, Beck Depression Inventory; ANX, state-anxiety; ANG, state-anger(ANX, ANG were measured with the Spielberger State Trait Personality Inventory; PSS, perceived stress scale; STAI.
**Study 10 [17] is the analysis of a sub-population of Study11 [18]. Study 12 is the analysis of a sub-population of a study within a systematic review of clinical trials [27].
Summary of improvements by symptoms
| | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | |||||||
| Pain | Muscle stiffness | 49.6 | | | | | 50 | | | | | 68.9 | 32.4 | | |
| Headache | | | 36.8 | | 33 | 47.2 | | | | | | ||||
| Cramps | | | 38 | | | | | | | | | ||||
| Backache | | | 51.3 | | | | | | | | | ||||
| Fatigue | | | 59.8 | | | 35.5 | | | 33.6 | 35 | | ||||
| General aches and pains | | | 35.6 | | | | | | | | | ||||
| Concentration | Insomnia | 54.9 | | | 19.8 | | | | 44.3 | | | 74.8 | | | |
| Forgetfulness | | | | | | | 52.1 | | | | | | |||
| Confusion | | | | | | | | | | | | | |||
| Stay at home | | 83.3 | | | | | | | | 49.7 | 41.8 | | |||
| Avoid social activities | | 100 | | | | | | | | 37.9 | 23.8 | | |||
| Autonomic reactions | Cold sweats | 49.6 | | | | | | | | | | | | | |
| Hot flashes | 95.7 | | | | | | | | | | | | | ||
| Water retention | Weight gain | 49.6 | | 97 | | | 50 | | | | | 68.9 | | | |
| Skin disorders | | | | | | | | | | | | ||||
| Painful breasts | | | 63 | | 58 | 21.9 | | | | | | ||||
| Swelling | | 86.7 | 48.4 | | | 31.9 | 74.6 | 27.8 | 31.5 | 28.9 | | ||||
| Negative affect | Crying | 54.9 | | | 41 | | 50 | | 71.2 | | 71.3 | 74.8 | | | |
| Anxiety | | 92.3 | 58.8 | | 38 | 39 | 65.7 | 43.9 | 44.3 | 29.7 | | ||||
| Restlessness | | | | | 42 | | | | | | | ||||
| Irritability | | | 58.6 | | | 35 | | | 35.6 | 36.5 | | ||||
| Mood swings | 78.9 | 91.6 | 59.2 | | | 49 | | | 31.8 | 34.6 | | ||||
| Depression | | 89 | 52.7 | | 52 | 52.8 | | | 42.9 | 27.7 | | ||||
| Tension | | | | | | | | | | | | ||||
| Other symptoms | Change in eating habits | | | | 45 | | 50 | | 43.6 | 77.6 | 21.6 | | | | |
| Abdominal bulging | 49.6 | 74.3 | 78.2 | 55 | | | 60 | | | | | | | | |
| Abdominal pain | 76.2 | 81.9 | | | | | | | | | | | | ||
| Sensitivity to cold | | | | | | | | | | | | | | ||
| Anger | 100 | 59.1 | 50.5 | 36.9 | |||||||||||
Treatment methods are numbered according to Tables 2 and 4. Improvements are recalculated using the following valuation: Significant result (%) = (baseline score-post treatment score)/baseline score) x100. The results were presented to reflect the results for symptom clusters.
AT: Acupuncture Treatment; Xy:Xiao Yao San; Es:Elsholtzia splendens; Cj:Cirsium japonicum; Gb:Ginkgo biloba L.; #: number according to Tables 2 and 3.